ORFIDAL Side Effects

6269734-0 | Hepatitis Cholestatic
on Jul 15, 2009 Male patient from SPAIN , 39 years of age, was diagnosed with anxiety (What is anxiety?) and was treated with Orfidal (View Usage). Patient experienced the following unwanted or unexpected effects: hepatitis cholestatic. Orfidal dosage: . During the same period patient was treated with VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), TRANKIMAZIN (View Trankimazin Review and Trankimazin Label ). Patient was hospitalized.

6263670-1 | Hepatitis Cholestatic
Patient was taking Orfidal (View Usage). Patient had the following side effects: hepatitis cholestatic on Jul 06, 2009 from SPAIN Additional patient health information: Male patient , 39 years of age, was diagnosed with anxiety (What is anxiety?) and. Orfidal dosage: . During the same period patient was treated with VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), TRANKIMAZIN (View Trankimazin Review and Trankimazin Label ). Patient was hospitalized.

5839951-X | Atrial Fibrillation, Cytolytic Hepatitis
Adverse event was reported on Jul 31, 2008 by a Female patient taking Orfidal (View Usage) (Dosage: ) . Location: SPAIN , 73 years of age, After Orfidal was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), cytolytic hepatitis. During the same period patient was treated with DACORTIN (View Dacortin Review and Dacortin Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), DANATROL (View Danatrol Review and Danatrol Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ). Patient was hospitalized.

5764751-9 | Blood Creatine Phosphokinase Increased, Confusional State, Hypernatraemia, Metabolic Acidosis, Neuroleptic Malignant Syndrome, Pyrexia
on Jun 02, 2008 Female patient from SPAIN , 64 years of age, was diagnosed with disorientation, alcohol detoxification, bipolar disorder (What is bipolar disorder?) and was treated with Orfidal (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatine phosphokinase increased, confusional state, hypernatraemia, metabolic acidosis, neuroleptic malignant syndrome, pyrexia. Orfidal dosage: . During the same period patient was treated with HALOPERIDOL (View Haloperidol Review and Haloperidol Label ), LITHIUM CARBONATE (View Lithium Carbonate Review and Lithium Carbonate Label ), ANTABUSE (View Antabuse Review and Antabuse Label ), ETUMINA (View Etumina Review and Etumina Label ), VANDRAL RETARD (View Vandral Retard Review and Vandral Retard Label ), AKINETON (View Akineton Review and Akineton Label ). Patient was hospitalized.


5460566-X | Abdominal Discomfort, Apallic Syndrome, Intentional Overdose, Loss Of Consciousness
on Aug 31, 2007 Female patient from SPAIN , 75 years of age, was diagnosed with sleep disorder (What is sleep disorder?), affective disorder and was treated with Orfidal (View Usage). Patient had the following side effects: abdominal discomfort, apallic syndrome, intentional overdose, loss of consciousness. Orfidal dosage: . During the same period patient was treated with CYMBALTA (480 Mg, Eight Tablets Of 60mg) (View Cymbalta Review and Cymbalta Label ). Patient was hospitalized.

5215201-2 | Aggression, Agitation, Confusional State, Dry Mouth, Fall, Nausea
Patient was taking Orfidal (View Usage). After Orfidal was administered, patient had the following side effects: aggression, agitation, confusional state, dry mouth, fall (What is fall?), nausea (What is nausea?) on Dec 29, 2006 from SPAIN Additional patient health information: Female patient , 84 years of age, was diagnosed with depression (What is depression?) and. Orfidal dosage: Po. During the same period patient was treated with CYMBALTA (60 Mg Q Day Po) (View Cymbalta Review and Cymbalta Label ).

5118905-5 | Renal Impairment
Adverse event was reported on Sep 11, 2006 by a Female patient taking Orfidal (View Usage) (Dosage: Df Po) . Location: SPAIN , 90 years of age, Patient experienced the following unwanted or unexpected effects: renal impairment. During the same period patient was treated with DILUTOL (5 Mg Qd Po) (View Dilutol Review and Dilutol Label ), CESPLON PLUS (1 Df Qd Po) (View Cesplon Plus Review and Cesplon Plus Label ). Patient was hospitalized.

5118423-4 | Hepatitis
on Sep 11, 2006 Female patient from SPAIN , 57 years of age, was diagnosed with colitis ulcerative and was treated with Orfidal (View Usage). Patient had the following side effects: hepatitis (What is hepatitis?). Orfidal dosage: 1 Mg Q Day Po. During the same period patient was treated with IMUREL (50 Mg Q Day Po) (View Imurel Review and Imurel Label ), ENTOCORT (View Entocort Review and Entocort Label ), URBASON /00049601/ (View Urbason /00049601/ Review and Urbason /00049601/ Label ).

5087093-6 | Dyskinesia
on Aug 03, 2006 Female patient from SPAIN , 76 years of age, was treated with Orfidal (View Usage). After Orfidal was administered, patient had the following side effects: dyskinesia. Orfidal dosage: 1 Mg Q Day Po. During the same period patient was treated with DEPRAX (100 Mg Q Day Po) (View Deprax Review and Deprax Label ), SEROQUEL (100 Mg Q Day Po) (View Seroquel Review and Seroquel Label ), DISTRANEURINE (View Distraneurine Review and Distraneurine Label ), EBIXA (View Ebixa Review and Ebixa Label ).

5003426-0 | Fall, Syncope
Patient was taking Orfidal (View Usage). Patient experienced the following unwanted or unexpected effects: fall (What is fall?), syncope on Apr 25, 2006 from SPAIN Additional patient health information: Female patient , 81 years of age, . Orfidal dosage: 1 Mg Q Day Po. During the same period patient was treated with NOBRITOL (1 Cap Q Day Po) (View Nobritol Review and Nobritol Label ). Patient was hospitalized.

4778687-3 | Stupor
Adverse event was reported on Sep 07, 2005 by a Male patient taking Orfidal (View Usage) (Dosage: 1 Mg Qd Po) was diagnosed with insomnia and. Location: SPAIN , 95 years of age, Patient had the following side effects: stupor. During the same period patient was treated with PARACETAMOL (View Paracetamol Review and Paracetamol Label ), DOPAMINE (View Dopamine Review and Dopamine Label ), SEGURIL (View Seguril Review and Seguril Label ), PHYTOMENADIONE (View Phytomenadione Review and Phytomenadione Label ), VENTOLIN (View Ventolin Review and Ventolin Label ).

4652521-4 | Agitation, Confusional State, Hallucination, Nervousness
on Apr 15, 2005 Female patient from , 60 years of age, was diagnosed with insomnia and was treated with Orfidal (View Usage). After Orfidal was administered, patient had the following side effects: agitation, confusional state, hallucination, nervousness. Orfidal dosage: 1 Mg Q Day Po. During the same period patient was treated with SEROQUEL (50 Mg Q Day Po) (View Seroquel Review and Seroquel Label ).